Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
73
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,515.20 | 3.70 | -0.04% |
CAC 40 | 7,226.98 | 199.90 | -2.69% |
DAX 40 | 19,033.64 | 414.96 | -2.13% |
Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
FTSE 100 | 8,025.77 | 99.42 | -1.22% |
HKSE | 19,846.88 | 580.05 | -2.84% |
NASDAQ | 19,281.40 | 17.36 | -0.09% |
Nikkei 225 | 39,376.09 | 157.23 | -0.40% |
NZX 50 Index | 12,684.56 | 64.80 | -0.51% |
S&P 500 | 5,983.99 | 17.36 | -0.29% |
S&P/ASX 200 | 8,255.60 | 10.60 | -0.13% |
SSE Composite Index | 3,421.97 | 48.10 | -1.39% |